Mould Illness
Functional Medicine Gold Coast
wave functional health
Dr Matt le Roux
When your environment has been making you sick and nobody has connected the dots
Mould illness and mycotoxin-driven chronic inflammatory response syndrome are among the most under-recognised causes of multi-system illness. At Wave Functional Health in Robina, we investigate biotoxin exposure as a root cause and build a structured, evidence-informed protocol to support recovery.
A diagnosis that hides in plain sight
If you have been sick since moving into a building, the building may be the reason
You have seen multiple practitioners. You have been tested for autoimmunity, thyroid disease, and depression. The results have come back largely normal, or you have received a diagnosis that does not fully explain your symptom burden. And yet you feel profoundly unwell across several body systems at once: exhausted, mentally slow, reactive to things that never bothered you before, and somehow worse in certain buildings or environments.
Mould illness occurs when exposure to water-damaged buildings, mould spores, or the mycotoxins they produce triggers a chronic inflammatory response in genetically susceptible individuals. Approximately 25 percent of the population carries an HLA-DR immune genotype that makes them unable to efficiently clear these biotoxins, leading to an immune response that persists long after the exposure ends.
At Wave Functional Health, we investigate biotoxin illness as a primary clinical framework for patients with unexplained multi-system illness, and we approach it with the same rigour and testing depth we apply to all complex chronic health presentations.
““I had been sick for three years. I had seen a rheumatologist, an immunologist, and two GPs. Nobody had ever asked me about my house. Six months after we found the mould and started the protocol, I had my life back.””
An important note. Mould illness investigation at Wave is conducted within a functional medicine framework and does not replace medical care for serious or life-threatening conditions. Where concurrent autoimmune, neurological, or respiratory disease is suspected, appropriate specialist referral is part of our clinical process.
Presentations We Work With
Patterns commonly seen in mould illness
Mould illness and biotoxin exposure can present across many body systems and are frequently misdiagnosed or attributed to other conditions. These are the patterns we most commonly investigate.
Common Presentations
Symptoms commonly associated with mould illness
Mould illness involves symptom patterns across multiple body systems simultaneously. The breadth and combination of symptoms often leads to misdiagnosis or no diagnosis at all.
Understanding the Condition
Why mould illness is complex and consistently misdiagnosed
Mould illness does not present as a single organ problem. It is a systemic inflammatory condition driven by immune dysregulation in response to biotoxin exposure. In genetically susceptible individuals, the immune system is unable to tag and clear mycotoxins efficiently, meaning they recirculate and continue triggering inflammatory responses through innate immune pathways long after the original exposure has ended.
This creates a condition that mimics and overlaps with fibromyalgia, autoimmune disease, depression, anxiety, chronic fatigue syndrome, and irritable bowel syndrome, which is why the average mould illness patient sees multiple practitioners across several years before an accurate understanding of their condition is reached. The ERMI (Environmental Relative Mouldiness Index) and HERTSMI-2 visual contrast sensitivity testing, alongside specific CIRS biomarker panels, are the tools that begin to make this picture legible.
The Immune and Neurological Connection
Why mould illness affects so many systems at once
The breadth of mould illness symptoms is not random. It reflects the central position that specific immune and neuroendocrine pathways occupy in regulating every system of the body. When mycotoxins trigger persistent innate immune activation, the downstream effects include disruption to the hypothalamic-pituitary axis, impaired production of MSH (which regulates sleep cycles, pain sensitivity, and immune tolerance), VEGF suppression which reduces capillary density and tissue oxygenation, and direct mitochondrial toxicity that impairs cellular energy production across all tissues.
The neurological effects of biotoxin illness are particularly significant and particularly dismissed in conventional settings. Cognitive impairment, word retrieval difficulties, emotional dysregulation, and what patients describe as feeling like they are thinking through wet concrete are consistent features of CIRS that have been correlated with abnormalities on functional brain imaging in research settings.
The gut is also heavily implicated. Mycotoxins are inhaled, ingested, and transdermally absorbed. They disrupt the gut microbiome, compromise intestinal barrier integrity, and create a secondary source of systemic immune activation that perpetuates the overall inflammatory burden even after mould exposure has ended. Gut assessment and support is a necessary component of any comprehensive mould illness recovery protocol.
A 2013 study by Shoemaker and colleagues demonstrated that patients with CIRS from water-damaged buildings show consistent abnormalities in a panel of inflammatory biomarkers including TGF-beta 1, MMP-9, VEGF, MSH, and VIP, which normalise with appropriate treatment.
PubMed: CIRS biomarkers and treatment response (2013) →Research has identified that HLA-DR immune genotyping explains why only a subset of building occupants develop chronic illness from the same exposure, with susceptible genotypes unable to mount an effective adaptive immune response to clear biotoxins.
PubMed: Genetic susceptibility and biotoxin illness →A 2020 systematic review of mycotoxin-related illness confirmed that occupational and residential mycotoxin exposure is associated with multi-system health effects including neurological, immunological, and respiratory manifestations across multiple published studies.
PubMed: Mycotoxin exposure and multi-system illness (2020) →Where Standard Care Falls Short
What conventional medicine typically misses in mould illness
These are the specific gaps between standard clinical workups and what is required to identify and address biotoxin-driven illness.
The exposure history is never taken
Standard medical consultations do not routinely ask about water damage, visible mould, damp smells, or symptom patterns related to specific buildings. Without this question, the connection between the environment and the illness is never made.
CIRS biomarkers are not standard tests
The specific immune markers used to identify and monitor CIRS, including TGF-beta 1, MMP-9, VEGF, MSH, C4a, and leptin, are not part of routine pathology panels. Standard inflammatory markers like CRP are often normal in mould illness despite significant immune dysregulation.
Urinary mycotoxins are rarely measured
Direct measurement of mycotoxin metabolites in urine, which provides evidence of mycotoxin burden within the body, is not offered in standard care. It requires specific functional pathology testing and is one of the most direct lines of evidence connecting the exposure to the clinical picture.
HLA-DR genotyping is not performed
Identifying whether a patient carries the susceptible HLA-DR immune genotype explains why they are sick when others in the same building are not. It is not part of any standard immunological workup and is rarely requested outside of specialist functional medicine practice.
Symptoms are attributed to other diagnoses
Mould illness mimics fibromyalgia, ME/CFS, depression, anxiety, and autoimmune disease closely enough that patients frequently receive one of these diagnoses and are treated without improvement, because the underlying biotoxin driver has not been identified.
Remediation and binders are not prescribed
Even when mould is identified as a clinical concern, conventional medicine rarely provides structured guidance on building remediation, mycotoxin binder therapy, or the sequenced protocol required for CIRS recovery. Without removing the exposure, symptom improvement is limited and recurrence is near-certain.
The Wave Approach
How we investigate and address mould illness
Recovery from mould illness requires a structured, sequenced approach. Attempting to detoxify without addressing the exposure source, or treating downstream symptoms without identifying the biotoxin burden, reliably produces poor outcomes. Our protocol follows the evidence-based CIRS framework and integrates functional testing, biotoxin binder therapy, gut support, and nervous system regulation.
Detailed environmental and symptom history
We take a thorough history of your residential, occupational, and vehicle environments, including any history of flooding, roof leaks, damp smells, visible mould, or symptom patterns correlated with time in specific buildings. We map the timeline of your illness against environmental exposures and document your full symptom burden across all body systems.
Functional and CIRS-specific diagnostic testing
Testing is selected based on your history and clinical picture and may include:
- Urinary mycotoxin panel
- HLA-DR immune genotyping
- CIRS biomarkers: TGF-beta 1, MMP-9, VEGF, C4a, MSH
- Visual Contrast Sensitivity (VCS) testing
- Comprehensive blood chemistry via OptimalDX
- Gut microbiome analysis: GI MAP or MicrobiomiX
- Organic acids for mitochondrial function
- Full thyroid and hormonal panel
- HRV assessment for autonomic function
- MARCoNS nasal culture where indicated
Exposure removal and environmental assessment
No recovery from mould illness is sustainable without addressing the source of exposure. We provide guidance on ERMI and HERTSMI-2 testing for the home environment, assist with interpretation of results, and support the process of identifying safe remediation or relocation where necessary. This step is non-negotiable for recovery.
Biotoxin binder therapy
Mycotoxin binders including cholestyramine, welchol, or natural alternatives such as bentonite clay and activated charcoal are used to bind mycotoxins in the gut and prevent enterohepatic recirculation. Binder selection and dosing is based on mycotoxin profile, gut function, and individual tolerance. This is a central component of the CIRS protocol and is not appropriate to self-administer without clinical guidance.
Gut microbiome repair and immune support
Mycotoxins are profoundly disruptive to the gut microbiome and intestinal barrier. Once the primary biotoxin burden is being addressed, we sequence gut repair protocols including dysbiosis treatment, mucosal lining support, and microbiome restoration. Gut health is also critical to the effectiveness of binder therapy and ongoing mycotoxin clearance.
Neurological and HPA axis support
Biotoxin illness profoundly disrupts the hypothalamic-pituitary axis, cortisol production, MSH levels, and autonomic nervous system function. HRV monitoring guides nervous system support, and Frequency Specific Microcurrent is used to address neuroinflammation, improve autonomic tone, and support the neurological recovery that standard detoxification protocols do not specifically target.
Sequential CIRS protocol and biomarker monitoring
Recovery from CIRS follows a specific sequence based on the Shoemaker protocol, addressing each abnormal biomarker in a defined order. We track CIRS biomarkers, VCS testing, mycotoxin burden, gut markers, and patient-reported outcomes at regular intervals throughout treatment and adjust the protocol as results evolve.
Condition Spotlight
MARCoNS and the nasal sinus dimension of mould illness
MARCoNS stands for Multiple Antibiotic Resistant Coagulase Negative Staph. It is a biofilm-forming bacterial colonisation of the deep nasal passages that is found in a significant proportion of patients with CIRS. It is not a standard infection and will not be detected by a routine nasal swab or treated by standard antibiotics.
MARCoNS perpetuates mould illness by producing exotoxins that further suppress MSH and disrupt hypothalamic function. This creates a self-perpetuating cycle where low MSH prevents effective immune clearance of MARCoNS, and MARCoNS continues to suppress MSH, making it extremely difficult to progress in the CIRS protocol without specifically addressing this colonisation.
Where MARCoNS is identified through a deep nasal culture performed by a specialist laboratory, treatment involves specific intranasal protocols designed to penetrate the biofilm. Identifying and treating MARCoNS is a critical but frequently overlooked step in mould illness recovery that explains why many patients plateau despite doing everything else correctly.
Advanced Diagnostics
Testing we use to investigate mould illness
Standard pathology is not designed to detect biotoxin burden or CIRS biomarker patterns. These are the tests that begin to make mould illness clinically legible.
← Scroll to see full table
| Test | What it assesses | Relevance to mould illness | Availability |
|---|---|---|---|
| Urinary Mycotoxin Panel | Direct measurement of mycotoxin metabolites including ochratoxin A, aflatoxins, gliotoxin, and trichothecenes in urine | Provides direct evidence of mycotoxin body burden and identifies the specific toxin classes driving illness to guide binder selection | Wave Functional Health |
| HLA-DR Immune Genotyping | Immune genotype assessment identifying susceptibility to biotoxin accumulation | Explains why this patient is sick when others in the same environment are not — a foundational diagnostic piece in the CIRS framework | Wave Functional Health |
| CIRS Biomarker Panel | TGF-beta 1, MMP-9, VEGF, C4a, MSH, VIP, leptin, ACTH, and cortisol | Identifies the specific innate immune and neuroendocrine pathways disrupted by biotoxin exposure and tracks treatment response over time | Via referral |
| Visual Contrast Sensitivity (VCS) | Neurological function test assessing contrast sensitivity as a proxy for biotoxin-related neurological impairment | A reproducible, objective marker of biotoxin-related neurological dysfunction that serves as a screening and monitoring tool throughout the CIRS protocol | Wave Functional Health |
| Comprehensive Blood Chemistry (OptimalDX) | Full metabolic, inflammatory, and nutrient panel at functional reference ranges | Assesses the downstream metabolic and inflammatory effects of biotoxin burden including liver stress, nutrient depletion, and inflammatory markers | Wave Functional Health |
| Metagenomics Microbiome Analysis | Full gut microbial ecosystem including bacteria, fungi, parasites, and functional markers | Identifies mycotoxin-driven gut dysbiosis, fungal overgrowth, and intestinal permeability disruption as secondary contributors to overall illness burden | Wave Functional Health |
| Organic Acids Testing | Mitochondrial function markers, Krebs cycle intermediates, mycotoxin metabolite indicators | Identifies mitochondrial toxicity from mycotoxin exposure and fungal metabolites including gliotoxin and citrinin as markers of ongoing internal toxin production | Wave Functional Health |
| MARCoNS Nasal Culture | Deep nasal culture identifying multiple antibiotic resistant Staph colonisation of the nasal biofilm | Identifies the nasal colonisation that perpetuates MSH suppression and prevents protocol progression — required where CIRS patients plateau despite treatment | Via referral |
| HRV Analysis | Autonomic nervous system function, vagal tone, and recovery capacity | Assesses the degree of autonomic disruption from biotoxin-related hypothalamic dysfunction and guides nervous system support throughout recovery | Wave Functional Health |
Who This Is For
This approach may suit you if...
Mould illness is worth investigating whenever the clinical pattern involves multiple body systems simultaneously, a history of living or working in a water-damaged building, and a lack of improvement with standard treatments across multiple practitioners.
You do not need a confirmed diagnosis of CIRS to begin an investigation. If the history and symptom pattern suggest biotoxin exposure as a plausible explanation for your illness, that is sufficient reason to investigate it properly.
Frequently Asked Questions
What people ask about mould illness at Wave
Yes. Visible mould represents only a fraction of the mould and mycotoxin burden in a water-damaged building. Mould grows inside wall cavities, under flooring, behind skirting boards, in ceiling spaces, and in HVAC systems.
The mycotoxins produced can be present at significant levels throughout a building even when no mould is visible. ERMI testing of settled dust provides a more reliable picture of overall mould burden than visual inspection alone.
Approximately 25 percent of the population carries an HLA-DR immune genotype that impairs the ability to tag and clear biotoxins including mycotoxins. In these individuals, biotoxins remain in circulation and continue triggering innate immune responses rather than being efficiently cleared.
The other 75 percent of people can generally clear biotoxins without developing chronic illness, which is why mould illness is often dismissed as others in the same building appear unaffected.
Recovery is possible for most patients when the exposure is successfully removed and a structured treatment protocol is followed. The prognosis is significantly better with earlier intervention and with adherence to the sequenced approach.
Some patients with long-standing CIRS and significant neurological involvement require a longer recovery timeline. We monitor progress objectively through biomarker tracking and patient-reported outcomes and adjust treatment throughout the process.
Beginning binder therapy or detoxification protocols while remaining in a mould-contaminated environment has a very limited chance of producing durable improvement. The ongoing exposure continues to drive immune activation faster than treatment can address it.
Exposure removal is the most critical step in recovery. We work with patients on practical strategies for managing this, including guidance on environmental testing, professional remediation, and interim steps where relocation is not immediately possible.
Children are potentially more vulnerable to the neurological and developmental effects of mycotoxin exposure given the active development of the brain and immune system in childhood. Presentations in children may include worsening attention, mood dysregulation, fatigue, recurrent illness, and behavioural changes that are often attributed to other causes.
Where a child is living in a water-damaged building and experiencing these patterns, biotoxin exposure is worth investigating as a contributing factor.
Porous items including upholstered furniture, mattresses, clothing, books, and paper can harbour mycotoxins and reintroduce biotoxin exposure after remediation. The extent to which belongings need to be replaced depends on the severity of the contamination, the specific mould species involved, and the individual's level of sensitivity.
We provide guidance on this as part of the exposure removal conversation and take a practical rather than an absolutist approach wherever possible.
If your environment has been making you sick,
it is time to find out for certain.
Book an initial functional medicine consultation at Wave Functional Health in Robina, Gold Coast. We will review your full history, your symptom pattern, and your environmental exposures, and build a clear investigative plan together.
Book Your Consultation